Pay in 4 interest-free payments of $5.52 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Journal of Dermatological Treatment, 23(2), 97-102
Can-Fite BioPharma completed enrollment of the first 247 patients, triggering the pre-specified interim analysis of its pivotal Phase 3 trial (NCT06643260) for piclidenoson, a first-in-class oral A3 adenosine receptor (A3AR) agonist, in moderate-to-severe plaque psoriasis
PMID 35691683
It was surprising that just one round of DMSA had significant behavioral effects, but this is consistent with the finding that just one round of DMSA was sufficient to normalize glutathione and improve platelet levels (a marker of inflammation)
US$ 27.40
US$ 27.90
US$ 29.97
